Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $94 | $112 | $113 | $119 |
| % Growth | -16.1% | -1% | -4.7% | – |
| Cost of Goods Sold | $39 | $46 | $53 | $51 |
| Gross Profit | $55 | $66 | $61 | $68 |
| % Margin | 58.2% | 58.9% | 53.7% | 56.9% |
| R&D Expenses | $10 | $12 | $12 | $11 |
| G&A Expenses | $21 | $23 | $24 | $24 |
| SG&A Expenses | $44 | $47 | $50 | $49 |
| Sales & Mktg Exp. | $22 | $24 | $25 | $25 |
| Other Operating Expenses | $7 | $6 | $6 | $6 |
| Operating Expenses | $61 | $64 | $68 | $66 |
| Operating Income | -$6 | $2 | -$7 | $2 |
| % Margin | -6.6% | 1.7% | -6.1% | 1.7% |
| Other Income/Exp. Net | -$5 | -$4 | -$2 | -$2 |
| Pre-Tax Income | -$12 | -$3 | -$9 | -$0 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | -$12 | -$3 | -$10 | -$0 |
| % Margin | -13.2% | -3% | -8.4% | -0.2% |
| EPS | -0.28 | -0.081 | -0.23 | -0.007 |
| % Growth | -247.8% | 65% | -3,139.4% | – |
| EPS Diluted | -0.28 | -0.081 | -0.23 | -0.007 |
| Weighted Avg Shares Out | 44 | 42 | 41 | 40 |
| Weighted Avg Shares Out Dil | 44 | 42 | 41 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $4 | $3 | $2 |
| Depreciation & Amortization | $7 | $7 | $8 | $8 |
| EBITDA | -$1 | $8 | $1 | $9 |
| % Margin | -1.6% | 7.2% | 0.8% | 7.6% |